Fig. 6: MiR-107 induces Th9 differentiation and IL-9 expression via inhibiting Foxp1 in CD4+ T cells.

A Naive CD4+ T cells were treated with 10 ng/mL human IL-4, 1 ng/mL human TGF-β, and 10 μg/mL anti-IFN-γ monoclonal antibodies to induce Th9 differentiation, and followed by the coculture with hepatocytes-derived exosomes (Vehicle-Exo, PA-Exo, PA + NCI-Exo, and PA + miR-107I-Exo). QRT-PCR was performed to examine the mRNA expression of Foxp1 in CD4+ T cells. B Luciferase report assay was performed to determine the binding of Foxp1 and miR-107. C CHIP was carried out to analyze the binding of Foxp1 and IL-9 promoter in CD4+ T cells. Flow cytometry and qRT-PCR were performed to examine Th9 cells proportion (D), and IL-9 mRNA expression (E) in CD4+ T cells. ****P < 0.0001 vs. Vehicle-Exo; ####P < 0.0001 vs. PA + NCI-Exo; $$$$P < 0.0001 vs. mimic NC; %%%%P < 0.0001 vs. IgG; &P < 0.05, &&P < 0.01, &&&&P < 0.0001 vs. Ctrl+ mimic NC; @@@@P < 0.0001 vs. Ctrl+ miR-107 mimic. Data were expressed as the mean ± standard deviation (n = 3).